 NPS is committed to developing new treatment options for patients with rare gastrointestinal and endocrine disorders who have few, if any, therapeutic options. We have completed Phase 3 registration studies for our two leading compounds — GATTEX® (teduglutide) for short bowel syndrome and NATPARA™ (recombinant human parathyroid hormone (rhPTH (1-84)) for hypoparathyroidism. We have provided information within this section to further educate you about SBS and hypoparathyroidism. |
|
